Assessment of the Effectiveness of Niclosamide as Add on Therapy to the Standard of care Measures in COVID-19 Management in a randomized controlled clinical trial
Protocol of therapy Niclosamaide Add on group
- NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on
the 2nd day 1g x3 for 7 days. [ this means only in the first day 4 gm/d then on the
second day 3g/d in 3 divided doses for 7 days]
- If the participant requires mechanical ventilation over the course of the study, NGT may
be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be
administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
Control group The patients in this group will receive only standard care which will include
all or some of the following, according to the clinical condition of each patient:
- Acetaminophen 500mg on need
- Vitamin C 1000mg twice/ day
- Zinc 75-125 mg/day
- Vitamin D3 5000IU/day
- Azithromycin 250mg/day for 5 days
- Oxygen therapy/ C-Pap if needed
- Dexamethasone 6 mg/day or methylprednisolone 40mg twice per day, if needed
- Mechanical ventilation, if needed
Drug: Niclosamide Oral Tablet
NCS 2 grams orally loading dose chewable then 1g every 8 hours in the first day, then on the 2nd day 1g x3 for 7 days. [ this means only in the first day 4 gm/d then on the second day 3g/d in 3 divided doses for 7 days]
If the participant requires mechanical ventilation over the course of the study, NGT may be administered via nasogastric (NG) or orogastric (OG) tube and, if possible, should be administered with a scheduled nasogastric (NG) or orogastric (OG) feeding.
Other Name: Yomesan
Inclusion Criteria:
1. Patients with age above 18 years and of any gender.
2. Definite diagnosis of COVID-19 according to the WHO classification criteria ( 18).
3. Patients symptomatic for no more than three days for mild-moderate cases, no more than
two days after being severe cases, and no more than one day after being critical
cases.
4. Understands and agrees to comply with planned study procedures.
Exclusion Criteria:
1. Patients refuse to enrol in the study
2. Patients with hypersensitivity or severe adverse effects to niclosamide
3. Renal impairment
4. Hepatic impairment
5. Pregnancy or a desire to become pregnant
6. Breast feeding
Ahmed S. Abdulamir
Baghdad, Baghdada, Iraq
Investigator: Ahmed S. Abdulamir, Professor
Contact: 009747702677741
ahmsah73@yahoo.com
Faiq I. Gorial, Professor
009647801730696
faiqig@yahoo.com